157 related articles for article (PubMed ID: 35280322)
1. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
Chao Y; Zhou J; Hsu S; Ding N; Li J; Zhang Y; Xu X; Tang X; Wei T; Zhu Z; Chu Q; Neal JW; Wu JT; Song Y; Hu J
Transl Lung Cancer Res; 2022 Feb; 11(2):295-306. PubMed ID: 35280322
[TBL] [Abstract][Full Text] [Related]
2. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
[TBL] [Abstract][Full Text] [Related]
3. Real-world incidence and risk factors of pneumonitis in chemoradiation plus immune checkpoint inhibitors compared with chemoradiation alone in lung cancer: a retrospective cohort study.
Pu D; Liu Q; Zhang S; Wang L; Xu F; Hofman P; Giusti R; Zhou Q; Li X; Li L
Transl Lung Cancer Res; 2024 Jan; 13(1):139-151. PubMed ID: 38405001
[TBL] [Abstract][Full Text] [Related]
4. Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
Wang X; Zhao J; Mei T; Liu W; Chen X; Wang J; Jiang R; Ye Z; Huang D
BMC Cancer; 2024 Feb; 24(1):269. PubMed ID: 38408928
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
[No Abstract] [Full Text] [Related]
8. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
[TBL] [Abstract][Full Text] [Related]
9. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients.
Araki T; Kanda S; Ide T; Sonehara K; Komatsu M; Tateishi K; Minagawa T; Kiniwa Y; Kawakami S; Nomura S; Okuyama R; Hanaoka M; Koizumi T
ESMO Open; 2023 Dec; 8(6):102030. PubMed ID: 37852033
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of PD-L1 and TMB for short-term efficacy prognosis in non-small cell lung cancer and construction of prediction models.
Shi S; Wang Y; Wu J; Zha B; Li P; Liu Y; Yang Y; Kong J; Gao S; Cui H; Huangfu L; Sun X; Li Z; Liang T; Zheng Y; Yang D
Front Oncol; 2024; 14():1342262. PubMed ID: 38756661
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study.
Huang H; Chen R; Xu Y; Fang N; Shao C; Xu K; Wang M
J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202262
[TBL] [Abstract][Full Text] [Related]
13. Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression.
Zhu X; Yu B; Shen Y; Zhao Y; Fu X; Zhu Y; Gu G; Liu C
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12965-12976. PubMed ID: 37468609
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics, Management and Prognostic Factors of Immune Checkpoint Inhibitor-Associated Pneumonia in Chinese Cancer Patients.
Li J; Chen S; Yan T; Zeng M
J Coll Physicians Surg Pak; 2024 Mar; 34(3):302-307. PubMed ID: 38462865
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management.
Lin MX; Zang D; Liu CG; Han X; Chen J
Front Immunol; 2024; 15():1266850. PubMed ID: 38426102
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis.
Li Y; Jia X; Zhang Y; Du Y; Chang Y; Shen Y; Mao Z; Liu M; Sun H; Guo H
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290926
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC.
Kimura N; Tsukita Y; Ebina-Shibuya R; Miyauchi E; Yamada M; Narita D; Saito R; Inoue C; Fujino N; Ichikawa T; Tamada T; Sugiura H
Cancer Biomark; 2024 Mar; ():. PubMed ID: 38669521
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case-control study.
Su J; Chen P; Yang Y; Gao Z; Bi Z; Feng M
BMJ Open; 2024 May; 14(5):e082484. PubMed ID: 38760047
[TBL] [Abstract][Full Text] [Related]
19. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Bui AN; Tyan K; Giobbie-Hurder A; Klein IA; Manos MP; Zubiri L; Reynolds K; Grover S; Weinhouse GL; Ott PA; LeBoeuf NR; Rahma O
J Immunother Precis Oncol; 2021 May; 4(2):35-44. PubMed ID: 35663537
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of Varicella-Zoster Virus in Patients with Lung Cancer Receiving Immune Checkpoint Inhibitors: Retrospective Nationwide Population-Based Cohort Study from South Korea.
Jung J; Park SY; Park JY; Kim D; Lee K; Choi S
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
